CI

At a glance

ClinicalIndex Comparison Record
Phase 2Active· 30 enrolled
Drug / intervention
Nivolumab +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02919683
NCT02919683Phase 2Active
CompareCT.gov

Window Study of Nivolumab With or Without Ipilimumab in Squamous Cell Carcinoma of the Oral Cavity

Dana-Farber Cancer Institute·interventional·Posted Sep 29, 2016·Updated Jan 28, 2026

In Brief

A Phase 2 clinical trial evaluating Nivolumab, Ipilimumab, and 1 other intervention for Head and Neck Cancer. Active but no longer recruiting, targeting 30 participants across 1 site.

Detailed Summary

This research study is studying nivolumab, an investigational drug, in combination with ipilimumab, also an investigational drug, as a possible treatment for Squamous Cell Carcinoma of the oral cavity. The following drugs are involved in this study: * Nivolumab (Opdivo™) * Ipilimumab (Yervoy™)

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHead and Neck Cancer
CountriesUnited States
CollaboratorsBristol-Myers Squibb

Timeline

Phase 2Active
20172018201920202021202220232024202520262027
First PostedSep 29, 2016
Enrollment StartNov 1, 2016
Primary CompletionJul 1, 2019
Study CompletionDec 1, 2026
TodayJul 2, 2026
Enrollment to primary: 2.7 yearsPosted 9.8 years ago

Interventions

Nivolumabdrug

Ipilimumabdrug

Standard of Care Surgeryprocedure